Lọc theo
The efficacy of maintenance with a modified biosimilar of infliximab in promoting healing of inflamed mucosa in CD is observed across all SES-CD segments, a post hoc analysis of the LIBERTY-CD trial has shown
In patients with colorectal cancer, a history of allergy, previous oxaliplatin exposure, and chemotherapy regimens appear to increase the risk of having oxaliplatin hypersensitivity reactions, results of a recent study have shown.
The disease-free survival outcome in patients with low rectal cancer who receive laparoscopic surgery compares favourably with that in those who receive open surgery, according to a study.
The Metagenome-Assembled Genome Inventory for Children (MAGIC) database, which contains 20,172 global gut metagenomes from humans aged 0–7 years, characterizes the bacteriome and virome diversity of the global gut microbiome in early life.
The novel α2δ ligand PD-217,014 does not appear to show any benefit in the treatment of patients with irritable bowel syndrome (IBS) or bowel habit subtypes, irrespective of their pain and anxiety levels, according to a study.
Individuals with inflammatory bowel disease (IBD) appear to be at greater risk of developing chronic obstructive pulmonary disease (COPD) and asthma, suggests a study.
The integrin receptor antagonist vedolizumab mostly works as well as the TNF-alpha inhibitor infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis treated in the real-world setting, although vedolizumab slightly surpasses infliximab in terms of inducing endoscopic response and remission while having a better safety profile, according to a study.
Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.
People with gallstone disease are at higher risk of inflammatory bowel disease (IBD), regardless of other traditional risk factors, according to a study.
RO7790121, an antibody against tumour necrosis factor-like ligand 1A (Anti-TL1A), helps improve the health-related quality of life (HR-QoL) for patients with moderately to severely active ulcerative colitis (UC), as shown in the phase IIb TUSCANY-2 trial.